Pembrolizumab shows promising OS for previously untreated advanced HCC

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.Immunotherapy as monotherapy can offer “excellent benefit” for around 25% to 30% of patients in this setting, or it can be used in combinations to provide new treatment options for patients with hepatocellular carcinoma, according to Jean-Luc Van Laethem, MD, PhD, of the department of gastroenterology and digestive oncology at Hôpital Erasme –Read More

Share on facebook
Share on twitter
Share on linkedin